2114 BLADDER CANCER INCIDENCE AND SURVIVAL IN ORGAN TRANSPLANT RECIPIENTS: THE UNIVERSITY OF WISCONSIN EXPERIENCE (2013)

You have accessJournal of UrologyTransplantation & Vascular Surgery: Renal Transplantation, Renal Vascular Surgery1 Apr 20132114 BLADDER CANCER INCIDENCE AND SURVIVAL IN ORGAN TRANSPLANT RECIPIENTS: THE UNIVERSITY OF WISCONSIN EXPERIENCE Tracy M. Downs, E. Jason Abel, Amy Powell, Glenn Leverson, David F. Jarrard, and Josh Mezrich Tracy M. DownsTracy M. Downs Madison, WI More articles by this author , E. Jason AbelE. Jason Abel Madison, WI More articles by this author , Amy PowellAmy Powell Madison, WI More articles by this author , Glenn LeversonGlenn Leverson Madison, WI More articles by this author , David F. JarrardDavid F. Jarrard Madison, WI More articles by this author , and Josh MezrichJosh Mezrich Madison, WI More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2023AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Population based studies have estimated the lifetime risk of malignancy after solid organ transplant to be increased two to four times compared to the general population. Few studies have described treatment outcomes for bladder cancer patients after transplant. The objective of our study was to evaluate the treatment outcomes of patients who are diagnosed with bladder cancer after solid abdominal organ transplant. METHODS The records of all consecutive patients who underwent solid abdominal organ transplantation at the University of Wisconsin Hospital from 1994 to 2010 were reviewed. RESULTS 6480 patients were eligible for study. Bladder cancer was identified in 17 patients after transplantation. 5 patients were excluded because bladder cancer was diagnosed within 3 months of transplantation. Bladder cancer diagnosis was made at a mean interval of 87 months following transplantation. Mean age at the time of bladder cancer diagnosis 60.3 years and mean follow−up 125 months. Superficial cancer was present in 7/12 patients. Treatment consisted of TUR only (3/7), intravesical chemotherapy (3/7) and cystectomy (1/7). No patients with superficial cancer died during follow−up period. Muscle invasive cancer was present in 5/12 patients. Cystectomy was performed in 3 patients (1 patient XRT, 1 patient refused treatment). 4/5 of these patients died at a median 430 days after diagnosis. CONCLUSIONS Bladder cancer presents at a more advanced stage in transplant recipients and stage ≥T2 has worse outcomes compared to non− transplant patients. Patients with superficial bladder cancer disease have survival outcomes comparable to the non−transplant bladder cancer patients. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e866 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tracy M. Downs Madison, WI More articles by this author E. Jason Abel Madison, WI More articles by this author Amy Powell Madison, WI More articles by this author Glenn Leverson Madison, WI More articles by this author David F. Jarrard Madison, WI More articles by this author Josh Mezrich Madison, WI More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...